Key facts
- Momentum Bioscience’s last known valuation is $25.2M.
- It has raised $19.5M; the latest was Later Stage VC ($1.3M) in Sep 2024.
- Notable investors include Innovate UK, SyndicateRoom, The FSE Group, Cambridge Angels, Development Bank of Wales — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Momentum Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Momentum Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Momentum Bioscience
Developer of an in-vitro diagnostic testing technology designed to offer rapid tests for critically important clinical specimens. The company's technology offers a suite of related systems for rapid detection of infection in blood and other normally sterile body fluids as well as for detecting all living bacteria and fungi, enabling microbiology laboratories to conduct tests for critically important clinical specimens.
- Sector
- Healthcare
- HQ
- Cardiff, United Kingdom
- Founded
- 2005
- Employees
- 15
- Website
- momentumbio.co.uk/
- Ownership
- Privately Held (backing)
Momentum Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Momentum Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Momentum Bioscience in its N-PORT filings yet. We sweep new filings monthly.